Surrozen Provides Second Quarter 2024 Financial Results and Business Update
12 août 2024 16h05 HE
|
Surrozen, Inc.
Surrozen Provides Second Quarter 2024 Financial Results and Business Update
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
04 juin 2024 08h30 HE
|
Surrozen, Inc.
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
03 avr. 2024 08h40 HE
|
Surrozen, Inc.
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
01 avr. 2024 08h30 HE
|
Surrozen, Inc.
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
Surrozen Provides Corporate Update on Clinical Programs
18 janv. 2024 08h30 HE
|
Surrozen, Inc.
Announces strategic prioritization of clinical programs to focus on development of SZN-043 for Alcohol-Associated Hepatitis SZN-043- Completed enrollment for the Phase 1a clinical trial in chronic...
Surrozen Provides Third Quarter 2023 Financial Results
08 nov. 2023 16h05 HE
|
Surrozen, Inc.
Expect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024 Expect to announce data from SZN-1326 Phase 1a clinical...